NCT07124546 Acceptance and Commitment Therapy for the Improvement of Cancer Distress in Patients With Incurable Cancers, ACT-C Trial
| NCT ID | NCT07124546 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Malignant Hepatobiliary Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-05-28 |
| Primary Completion | 2027-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-05-28 with a primary completion date of 2027-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether Acceptance and Commitment Therapy can be used to help improve cancer distress for patients with hepatobiliary or breast cancers for which no treatment is currently available (incurable). Patients with hepatobiliary cancer (HBC) and breast cancer often experience high levels of distress and reductions in quality of life. Acceptance and Commitment Therapy for incurable cancers (ACT-C) is a behavioral intervention tailored to patients with incurable HBC and breast cancer. It helps patients cope with difficult thoughts and emotions while staying connected to what matters most in life, which may be an effective way to improve cancer distress.
Eligibility Criteria
Inclusion Criteria: * Incurable HBC and breast cancer diagnosis * Age \>= 18 years * Able to provide written informed consent * Verbally endorse cancer distress * Access to the internet * Read and write in English * Reside in the states of Minnesota Exclusion Criteria: * Other psychological therapy that started =\< 2 months prior to prospective enrollment * Inability to actively participate in and learn from group therapy (e.g., active/uncontrolled psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgement in Behavioral Medicine Program (BMP) consultation. Individual therapy or alternative group therapy will be offered to patients ineligible per this criterion * Cancer remission
Contact & Investigator
Carrie A Bronars, PhD, LP
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT07124546 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Hepatobiliary Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07124546 currently recruiting?
Yes, NCT07124546 is actively recruiting participants. Contact the research team at Hammel.Sofia@mayo.edu for enrollment information.
Where is the NCT07124546 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT07124546 clinical trial?
NCT07124546 is sponsored by Mayo Clinic. The principal investigator is Carrie A Bronars, PhD, LP at Mayo Clinic in Rochester. The trial plans to enroll 60 participants.